David Hutton
University of Michigan
Professor, Health Sciences
United States
My Publications
Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, n...
Journal of Medical Economics
January 2019
Switching To Less Expensive Blindness Drug Could Save Medicare Part B $18 Billion Over ...
Health Affairs
June 2014